Drug · CDK4/6 inhibitor · CDK4/6 inhibitor · Verified drug
Palbociclib (Ibrance) structure · mechanism
CDK4/6 inhibitor combined with endocrine therapy.
Palbociclib (Ibrance) 2D structure
- Role
- Drug
- Mechanism class
- CDK4/6 inhibitor
- Aliases
- ibrance
- Parent scaffold
- Pyrrolopyrimidine CDK4/6 core
- Structure source
- Catalog seed (external identifier on file)
- PubChem CID
- 5330286
- ChEMBL ID
- CHEMBL189963
Hand-written analysis
Mechanism
팔보시클립은 CDK4/6를 저해해 Cyclin D–Rb 축의 G1→S 진행을 막습니다. ER+ HER2− 유방암에서 내분비 요법과 병용합니다. CDK2 여유도가 호중구감소와 관련됩니다.
Medicinal chemistry
피리도피리미딘 코어가 이 약의 케모타입입니다. 간헐 투약(3주 복용 1주 휴약)이 혈액학적 독성을 관리합니다.
Indication · context
HR+ 진행성 유방암의 1세대 CDK4/6입니다. 리보시클립·아베마시클립과 코어·투약 스케줄을 비교합니다.
SMILES
CC1=CC(=CC(=C1)C2=NC3=C(C=C(C=C3)N(C)C)N=C2N)N4CCNCC4Tags
Related compounds
Comparisons · briefs
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.